Analytical and histological characterization of nonalcoholic fatty liver in patients with diabetes type II

Authors

  • Esther Lidia González González Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Victor Manuel López Mejia Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Sarah Esther Díaz Oliva Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Merlyn Arce Núñez Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Yosvany Medina Garrido Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Marila Suárez González Hospital “Daniel Codorniú Pruna”, Placetas, Villa Clara, Cuba

Keywords:

fatty liver, diagnosis, histology, ultrasonography, obesity, abdominal, diabetes mellitus, type 2

Abstract

Nonalcoholic fatty liver is frequently associated to diabetes mellitus not insulin-dependent. In order to describe its biochemical, sonographic and histological aspects in a group of diabetic patients non-insulin dependent it was realized a cross-sectional descriptive study at “Arnaldo Milián Castro” Hospital in the period between September 2013 and January 2016. The sample was consisted of 22 patients who were underwent to determination of waist/hip index, analytical evaluation and the findings were pointed out histopathological of the liver. The relationships between some risk factors of progression of the disease and the results of liver biopsy were described. The glycemia was the most altered biochemical parameter (81.8%), followed by alanine aminotransferase and lipid profile (77.3% each one); 68.2% of patients had steatohepatitis with fibrosis; the alanine aminotransferase rose by 77.3% of patients with steatohepatitis and a significant association between the last and the increase of waist/hip index was found. Advanced stages should be suspected in nonalcoholic fatty liver in patients with diabetes non-insulin dependent.

Downloads

Download data is not yet available.

Author Biographies

Esther Lidia González González, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Medicina General Integral y en Gastroenterología. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Victor Manuel López Mejia, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Medicina General Integral. Residente de Gastroenterología.

Sarah Esther Díaz Oliva, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Gastroenterología. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Merlyn Arce Núñez, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I y II Grado en Gastroenterología. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Yosvany Medina Garrido, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Medicina General Integral. Especialista de II Grado en Gastroenterología. Profesor Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Marila Suárez González, Hospital “Daniel Codorniú Pruna”, Placetas, Villa Clara, Cuba

Especialista de I Grado en Medicina General Integral y en Gastroenterología. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

References

1. Callen L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem [Internet]. 2012 [citado 10 Feb 2016];77(3):287(25):20851-65. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22532560

2. Valenzuela C, Castillo V, Ronco AM, Aguirre C, Hirsch S, Llanos M. Sistema endocanabinoide y esteatosis hepática. Rev Méd Chile [Internet]. 2014 [citado 10 Feb 2016];142(3):353-360. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000300010

3. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol [Internet]. 2011 [citado 10 Feb 2016];163(7):1432-40. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21457226

4. Louvet A, Texeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, et al. Cannabinoid CB2 receptors protects against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology [Internet]. 2011 [citado 10 Feb 2016];54(4):1217-26. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21735467

5. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis [Internet]. 2012 [citado 10 Feb 2016];32(1):14-21. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22418884

6. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta [Internet]. 2012 [citado 10 Feb 2016];1821(5):809-18. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22056763

7. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia [Internet]. 2012 [citado 10 Feb 2016];55(4):885-904. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22278337

8. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. J Diabetes Res [Internet]. 2012 [citado 10 Feb 2016];2012 ID 716404:[aprox. 13 p.]. Disponible en: http://www.hindawi.com/journals/jdr/2012/716404/

9. Liechti F, Dufour JF. Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol [Internet]. 2012 [citado 10 Feb 2016];36 Suppl 1:S46-52. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23141894

10. Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol [Internet]. 2012 [citado 10 Feb 2016];107(7):976-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22764020

11. Kim MS, Kung S, Grewal T, Roufogalis BD. Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD). Curr Pharm Biotechnol Internet]. 2011 [citado 10 Feb 2016];13(2):278-291.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21470125

12. Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl) [Internet]. 2011 [citado 10 Feb 2016];90(2):105-118. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21894552

13. Caporaso N, Morisco F, Camera S, Graziani G, Donnarumma L, Ritieni A. Dietary approach in the prevention and treatment of NAFLD. Front Biosci (Landmark Ed) [Internet]. 2012 [citado 10 Feb 2016];17:2259-68. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22652776

14. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol [Internet]. 2011 [citado 10 Feb 2016];9(7):372-381. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22565095

15. Okanoue T. Recent progress in the research of NASH/ NAFLD in Japan. Nihon Shokakibyo Gakkai Zasshi [Internet]. 2011 [citado 10 Feb 2016];108(7):1161-1169. Disponible en: https://www.jstage.jst.go.jp/article/nisshoshi/108/7/108_7_1161/_pdf

16. Valenzuela CA, Castillo VA, Aguirre CA, Ronco AM, Llanos MN. The CB1 receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress. Obesity (Silver Spring) [Internet]. 2011 [citado 10 Feb 2016];19(1):29-35. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20559305

17. Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology [Internet]. 2012 [citado 10 Feb 2016];142(5):1218-1228. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22307032

18. Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab [Internet]. 2012 [citado 10 Feb 2016];16(2):167-79. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22841573

19. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology [Internet]. 2010 [citado 10 Feb 2016;52(2):472-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20683947

20. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol [Internet]. 2011 [citado 10 Feb 2016];163(7):1432-40. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21457226

21. McLarnon A. Liver: potential of resistance exercise as a lipid-lowering treatment for NAFLD that is independent of weight loss. Nat Rev Gastroenterol Hepatol [Internet]. 2011 [citado 10 Feb 2016];8:476. Disponible en: http://www.nature.com/nrgastro/journal/v8/n9/full/nrgastro.2011.137.html

Downloads

Published

2016-10-03

How to Cite

1.
González González EL, López Mejia VM, Díaz Oliva SE, Arce Núñez M, Medina Garrido Y, Suárez González M. Analytical and histological characterization of nonalcoholic fatty liver in patients with diabetes type II. Acta Méd Centro [Internet]. 2016 Oct. 3 [cited 2025 Jul. 3];10(4):36-45. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/761

Issue

Vol. 10 No. 4 (2016): October-December

Section

Original Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).